Short description
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers.
Description
Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. Their pipeline has recently expanded and now includes two clinical-stage
products with common regulatory and development strategies.
Oncternal Therapeutics cutting-edge scientific approach is focused on targets that are uniquely expressed within cancer cells, resulting in highly targeted new therapies. They also apply a variety of therapeutic strategies to address different medical challenges - from antibodies and antibody-drug conjugates (ADCs) to small molecules and chimeric antigen receptor T-cells (CAR-T).
Last funding
Nopepepe
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Encinitas, California, United States, North America
Founded on
January 1, 2013
Exited on
June 10, 2019
Went public on
June 10, 2019
Stock symbol
ONCT
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Cannot Access, Cannot Access
Sign in for full access
Founders
Lauren G. Otsuki, Scott Glenn